Cargando…

Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice

Introduction. The aim of this retrospective study was to examine effect of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) in second-line and further therapy in daily clinical practice. Methods. Patients with histologically or cytologically proven NSCLC (n = 84) treated with e...

Descripción completa

Detalles Bibliográficos
Autores principales: Krainhöfer, Josephine, Walther, Mario, Steinert, Matthias, Reissig, Angelika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084583/
https://www.ncbi.nlm.nih.gov/pubmed/25028671
http://dx.doi.org/10.1155/2014/987150
_version_ 1782324553944399872
author Krainhöfer, Josephine
Walther, Mario
Steinert, Matthias
Reissig, Angelika
author_facet Krainhöfer, Josephine
Walther, Mario
Steinert, Matthias
Reissig, Angelika
author_sort Krainhöfer, Josephine
collection PubMed
description Introduction. The aim of this retrospective study was to examine effect of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) in second-line and further therapy in daily clinical practice. Methods. Patients with histologically or cytologically proven NSCLC (n = 84) treated with erlotinib in second-line (n = 34), third-line (n = 36), and more-line therapy (n = 14) were examined for progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of therapy, and adverse effects. Results. Median PFS of all lines was 83 days (CI 70.0–96.0), OS was 7 months (CI 4.7–9.3), DCR was 66.2% (CI 55–77%), and 1-year survival rate was 33% (CI 22–43%), with no significant difference between therapy lines. Median duration of treatment was 76 days (IQR 39–139.5). Patients with epidermal growth factor receptor mutation (EGFR-M) reached the highest PFS (204 days), as did patients with good performance status (ECOG 0-1: 94 versus ECOG 2-3: 65 days, P = 0.035). Patients with EGFR-M also revealed a DCR of 100%. The most frequent side effects were rash (69%) and diarrhoea (41%), without any significant difference between therapy lines. In 24 patients, the treatment dose was reduced and in 18, the therapy was paused. Conclusion. Erlotinib works in all therapy lines without any significant differences in efficacy and side effects.
format Online
Article
Text
id pubmed-4084583
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-40845832014-07-15 Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice Krainhöfer, Josephine Walther, Mario Steinert, Matthias Reissig, Angelika Biomed Res Int Clinical Study Introduction. The aim of this retrospective study was to examine effect of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) in second-line and further therapy in daily clinical practice. Methods. Patients with histologically or cytologically proven NSCLC (n = 84) treated with erlotinib in second-line (n = 34), third-line (n = 36), and more-line therapy (n = 14) were examined for progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of therapy, and adverse effects. Results. Median PFS of all lines was 83 days (CI 70.0–96.0), OS was 7 months (CI 4.7–9.3), DCR was 66.2% (CI 55–77%), and 1-year survival rate was 33% (CI 22–43%), with no significant difference between therapy lines. Median duration of treatment was 76 days (IQR 39–139.5). Patients with epidermal growth factor receptor mutation (EGFR-M) reached the highest PFS (204 days), as did patients with good performance status (ECOG 0-1: 94 versus ECOG 2-3: 65 days, P = 0.035). Patients with EGFR-M also revealed a DCR of 100%. The most frequent side effects were rash (69%) and diarrhoea (41%), without any significant difference between therapy lines. In 24 patients, the treatment dose was reduced and in 18, the therapy was paused. Conclusion. Erlotinib works in all therapy lines without any significant differences in efficacy and side effects. Hindawi Publishing Corporation 2014 2014-06-17 /pmc/articles/PMC4084583/ /pubmed/25028671 http://dx.doi.org/10.1155/2014/987150 Text en Copyright © 2014 Josephine Krainhöfer et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Krainhöfer, Josephine
Walther, Mario
Steinert, Matthias
Reissig, Angelika
Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice
title Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice
title_full Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice
title_fullStr Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice
title_full_unstemmed Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice
title_short Second- and Further-Line Therapy with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer in Daily Clinical Practice
title_sort second- and further-line therapy with erlotinib in patients with advanced non-small-cell lung cancer in daily clinical practice
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084583/
https://www.ncbi.nlm.nih.gov/pubmed/25028671
http://dx.doi.org/10.1155/2014/987150
work_keys_str_mv AT krainhoferjosephine secondandfurtherlinetherapywitherlotinibinpatientswithadvancednonsmallcelllungcancerindailyclinicalpractice
AT walthermario secondandfurtherlinetherapywitherlotinibinpatientswithadvancednonsmallcelllungcancerindailyclinicalpractice
AT steinertmatthias secondandfurtherlinetherapywitherlotinibinpatientswithadvancednonsmallcelllungcancerindailyclinicalpractice
AT reissigangelika secondandfurtherlinetherapywitherlotinibinpatientswithadvancednonsmallcelllungcancerindailyclinicalpractice